• 1.

    Goldsmith DJ. Pro: Should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? Nephrol Dial Transplant 2016; 31:698705.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Goldsmith D, et al.. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant 2015; 30:698700.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Pfeffer MA, et al.. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:20192032.

  • 4.

    EVOLVE Trial Investigators , et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:24822494.

  • 5.

    Cunningham J, et al.. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:17931800.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Parfrey PS, et al.. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial. J Clin Endocrinol Metab 2013; 98:48344844.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Reams BD, et al.. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: A retrospective new-user cohort design. BMC Nephrol 2015; 16:175.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Evenepoel P, et al.. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 2014; 14:25452555.

    • Crossref
    • Search Google Scholar
    • Export Citation

The Case for Earlier/Targeted Treatment of Hyperparathyroidism with Cinacalcet: Calcimimetics Have Much to Offer the “Right” Patient

  • 1 Professor David Goldsmith, MA, MB BChir, FRCP (Lond), FRCP (Ed), FASN, is a consultant nephrologist, Guy’s and St Thomas’ Hospitals, and professor, Cardiovascular and Cell Sciences Institute, St George’s University of London.
Restricted access

In the therapy of hypertension, diabetes, or dyslipidemia or the attempt to prevent solid organ transplant rejection, it is a well recognized strategy to use a number of complementary pharmacologic approaches to address the fundamental goal, whether it is achieving better control of blood pressure (BP), blood sugar, or blood lipids, or long-term allograft survival. Monotherapy can work well, of course, in all of these settings, but usually only with milder disease states and only with good patient adherence and responsiveness to that single intervention. More often than not, we blend synergistic approaches, maximizing response while minimizing toxicity.

One has

Save